Xilio Therapeutics Files 8-K: Material Agreement, Other Events
Ticker: XLO · Form: 8-K · Filed: Jun 3, 2025 · CIK: 1840233
Sentiment: neutral
Topics: material-agreement, disclosure, filing
TL;DR
Xilio signed a big deal and filed an 8-K. Check it out.
AI Summary
On June 2, 2025, Xilio Therapeutics, Inc. entered into a material definitive agreement. The company also made a Regulation FD disclosure and reported other events. Financial statements and exhibits were filed as part of this report.
Why It Matters
This filing indicates significant corporate activity for Xilio Therapeutics, including a new material agreement and other disclosures that could impact investors.
Risk Assessment
Risk Level: medium — Material definitive agreements and other events reported on an 8-K can signal significant changes or developments for a company, warranting investor attention.
Key Players & Entities
- Xilio Therapeutics, Inc. (company) — Registrant
- June 2, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-40925 (identifier) — SEC File Number
- 85-1623397 (identifier) — IRS Employer Identification No.
- 828 Winter Street, Suite 300 Waltham, Massachusetts 02451 (address) — Principal Executive Offices
- (857) 524-2466 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by Xilio Therapeutics?
The filing states that Xilio Therapeutics, Inc. entered into a material definitive agreement on June 2, 2025, but the specific details of this agreement are not provided in the provided text.
What are the key items reported in this 8-K filing?
The key items reported are the entry into a material definitive agreement, a Regulation FD disclosure, other events, and the filing of financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on June 2, 2025.
Where is Xilio Therapeutics, Inc. headquartered?
Xilio Therapeutics, Inc. is headquartered at 828 Winter Street, Suite 300, Waltham, Massachusetts 02451.
What is the SEC file number for Xilio Therapeutics, Inc.?
The SEC file number for Xilio Therapeutics, Inc. is 001-40925.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 3, 2025 regarding Xilio Therapeutics, Inc. (XLO).